Latest articles on AI, technology, and software development.
Casgevy's FDA approval for sickle cell disease proved that CRISPR gene editing works as medicine. Now the field faces harder problems: manufacturing at scale, in-vivo delivery to tissues beyond the liver, and pricing structures that determine who actually benefits.
Google's Willow chip demonstrated below-threshold quantum error correction in December 2024 — the point where adding more physical qubits actually reduces logical error rates. Here's what that means for fault-tolerant computing timelines, cryptography, and your organization's security posture.
Three well-funded private fusion companies have crossed engineering milestones that were unthinkable a decade ago — here is a hard look at what each has actually built, what remains unproven, and when the grid might see the first fusion electrons.
The mRNA technology that proved itself during COVID-19 is now targeting cancer. Phase 2 results from Moderna and Merck showed a 49% reduction in melanoma recurrence. Phase 3 trials are enrolling, and BioNTech has data from pancreatic cancer — one of the hardest targets in oncology. Here is what the trials are showing.
GLP-1 receptor agonists were approved to treat diabetes and then became a blockbuster weight-loss category. Now researchers are finding the drugs appear to reduce addiction, depression, and possibly neurodegeneration — and no one fully understands why.
Aging biology has moved from philosophy to molecular targets. Senolytics are clearing senescent cells in human trials, Altos Labs began safety testing in 2025, and epigenetic clocks can now measure how fast you're aging — not just how old you are.
Quantum computing has promised transformative results for decades while struggling with a fundamental obstacle: physical qubits are fragile, error-prone, and decohere in microseconds. A series of landmark results published in 2025 and early 2026 suggest the field has genuinely turned a corner on error correction — the core technical problem that separates useful quantum computers from the expensive experiments of the last decade.
Noland Arbaugh became the first human to receive a Neuralink implant in January 2024, controlling a computer cursor with his thoughts. He's one of several patients across competing companies demonstrating that invasive BCIs work at a basic level. The harder questions — scale, safety, longevity, and what these devices can actually do — are now the frontline.
Researchers at the University of Cambridge used AI to identify a structural region conserved across the entire coronavirus family — from SARS-CoV-2 and its variants to MERS and bat coronaviruses not yet seen in humans. The resulting experimental pan-coronavirus vaccine has now completed a Phase I human trial in the UK, demonstrating a safety profile that clears the path to larger efficacy studies. Here is what the science actually showed, and what it does not yet prove.
GLP-1 receptor agonists were approved for type 2 diabetes. Then they turned out to reduce cardiovascular events, treat addiction, and slow cognitive decline. The class of drug may be the most consequential pharmacological discovery since statins.
DeepMind's AlphaFold 3 can predict the structure of proteins, DNA, RNA, and small molecules together. A year after broad access opened, drug discovery labs and academic researchers are starting to show what that capability actually unlocks.
Google's Willow chip demonstrated for the first time that adding more qubits actually reduces errors — the central unsolved problem of quantum computing. The physics is revolutionary; practical applications are still a decade away.